Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.

Phase 1RecruitingNCT07645534

Valenta Pharm JSC36 enrolled

Overview

This study aims to evaluate the safety and pharmacokinetic profile of the active ingredients Ingavirin forte, capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) relative to single-entity Drug Ingavirin, capsules, 90 mg following administration under fasting and fed conditions.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Influenza Acute Respiratory Viral Infections

Interventions

Ingavirin forte, capsules, 90 mg + 20 mg

Ingavirin forte containing 90 mg of imidazolylethanamide of pentanedioic acid and 20 mg of N,N'-bis-\[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl\] diamide of malonic acid (XC9)

Ingavirin, capsules, 90 mgDRUG

Ingavirin containing 90 mg of imidazolylethanamide of pentanedioic acid

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Voluntarily and personally signed Informed Consent Form (ICF) by a participant obtained prior to the conduct of any study-related procedure; 2. Males and females aged 18 to 45 years (inclusive); 3. Confirmed healthy status, defined as the absence of clinically significant abnormalities based on clinical evaluation, laboratory assessments, and diagnostic procedures as specified in the protocol; 4. Blood pressure (BP) level: systolic blood pressure (SBP) from 100 to 130 mmHg (inclusive), diastolic blood pressure (DBP) from 70 to 85 mmHg (inclusive); 5. Heart rate (HR) from 60 to 89 beats/min (inclusive); 6. Respiratory rate (RR) from 12 to 20 per minute (inclusive); 7. Body temperature from 36.0°C to 36.9°C (inclusive); 8. Body mass index (BMI) of 18.5 kg/m² ≤ BMI ≤ 30 kg/m², with body weight for men being ≥ 55 kg and for women ≥ 45 kg; 9. Agreement to use adequate methods of contraception throughout the study and for 30 days after its completion; for women of childbearing potential - a negative urine β-hCG test result; 10. Subjects must demonstrate appropriate behavior and coherent speech; 11. Ability to comply with the daily routine and diet prescribed by the study protocol. Noninclusion Criteria: 1. Clinically significant allergic history; 2. History of hypersensitivity to imidazolylethanamide of pentanedioic acid and N,N'-bis-\[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl\] diamide of malonic acid (XC9) and/or to the excipients contained in the investigational medicinal product; 3. History of drug intolerance to imidazolylethanamide of pentanedioic acid and N,N'-bis-\[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl\] diamide of malonic acid (XC9) and/or to the excipients contained in the investigational medicinal product; 4. Known galactose intolerance, lactase deficiency, or glucose-galactose malabsorption; 5. Chronic diseases of the kidneys, liver, gastrointestinal (GI) tract, cardiovascular, lymphatic, respiratory, nervous, endocrine, musculoskeletal, genitourinary, or immune systems, or of the skin, hematopoietic organs, or eyes; 6. History of gastrointestinal (GI) surgical procedures, with the exception of appendectomy performed at least 1 year prior to screening; 7. Diseases/conditions that, in the investigator's opinion, may affect the absorption, distribution, metabolism, or excretion of the investigational medicinal product (IMP); 8. Acute infectious diseases less than 4 weeks prior to screening; 9. Use of medicinal products (MPs) that have a pronounced effect on hemodynamics, MPs affecting liver function (barbiturates, omeprazole, cimetidine, etc.), MPs prolonging the QT interval (antipsychotics (haloperidol, quetiapine, olanzapine, risperidone, sulpiride), antidepressants (fluoxetine, sertraline), antiarrhythmics (amiodarone), antibiotics (clarithromycin, azithromycin, moxifloxacin, levofloxacin, ciprofloxacin), antifungals (fluconazole), diuretics (furosemide)) less than 2 months prior to screening; 10. Regular use of MPs less than 2 weeks prior to screening and single use of MPs less than 7 days prior to screening (including over-the-counter MPs, vitamins, dietary supplements, herbal medicinal products); 11. Donation of blood or plasma less than 3 months prior to screening; 12. Use of hormonal contraceptives by womeninitiated less than 2 months prior to the screening visit. 13. Use of depot injections of any MPs less than 3 months prior to the start of screening; 14. Pregnancy or breastfeeding; positive urine pregnancy test result for women of childbearing potential; 15. Women of childbearing potential with a history of unprotected sexual intercourse within 30 days prior to study drug administration with a non-sterilized partner; 16. Participation in another clinical trial within 3 months prior to screening or concurrently with the current study. 17. Consumption of more than 10 standard alcohol units per week during the month prior to study enrollment, (1 standard unit = 500 mL beer, 200 mL wine, or 50 mL of strong alcoholic beverages), or history of alcoholism, drug dependence, or substance abuse. 18. Currently smoking more than 10 cigarettes per day, or a history of smoking the specified number of cigarettes within the 6 months preceding screening; refusal to abstain from smoking while staying at the study center; 19. Consumption of alcohol, caffeine, and xanthine-containing products within 7 days prior to IMP administration; 20. Consumption of citrus fruits, cranberries, rose hips and products containing them, or St. John's wort-containing preparations or products within 7 days prior to IMP administration; 21. Dehydration due to diarrhea, vomiting, or other causes within the last 24 hours prior to IMP administration; 22. Positive blood test result for antibodies to human immunodeficiency virus (HIV) 1 and 2, antibodies to Treponema pallidum antigens, hepatitis B surface antigen (HBsAg), or antibodies to hepatitis C virus antigens at screening; 23. Clinically significant abnormalities on the electrocardiogram (ECG) in the medical history and/or at screening, including: QTcF interval (corrected by Fredericia) ≥430 ms in men and ≥450 ms in women; 24. History of risk factors for torsades de pointes, such as heart failure, hypokalemia, or family history of long QT syndrome; 25. Electrolyte imbalances (based on Na+, K+, Cl- levels at screening); 26. Positive urine test for narcotic substances and potent medicinal products at screening; 27. Positive breath alcohol test at screening; 28. Planned hospitalization during the study period for any reason other than hospitalization required by this protocol; 29. Inability or incapacity to comply with the protocol requirements, perform protocol-specified procedures, or adhere to the diet and activity restrictions; 30. Belonging to a vulnerable group of volunteers: students of higher and secondary medical, pharmaceutical, and dental educational institutions; subordinate clinical or laboratory staff; employees of pharmaceutical companies; military personnel and prisoners; residents of long-term care facilities; low-income and unemployed individuals; representatives of national minorities; homeless individuals; refugees; individuals under guardianship or trusteeship; persons incapable of providing informed consent; as well as law enforcement officers; 31. Any other condition which, in the Investigator's judgment, would preclude the subject's enrollment in the study or could lead to premature withdrawal, including adherence to fasting practices or special diets (e.g., vegetarian, vegan, sodium-restricted) or lifestyle factors (e.g., night shift work, extreme physical exertion). Exclusion criteria: 1. Subject's decision to discontinue participation in the study; 2. Subject non-compliance with protocol requirements, including but not limited to missed study procedures, unauthorized use of prohibited concomitant medications, or failure to adhere to protocol-defined dietary and lifestyle restrictions. 3. Occurrence of any medical condition or safety concern during study participation that could compromise subject safety (e.g., hypersensitivity reactions, etc.); 4. Subjects enrolled in the study despite not meeting eligibility criteria (inclusion/exclusion criteria violations). 5. Prolongation of the QTcF interval on ECG recording (\>500 ms or \>60 ms compared to baseline measured on Days 1, 8, 15, and 22); 6. Occurrence of a severe adverse event (AE) and/or serious adverse event (SAE) during study participation 7. Missed collection of two or more consecutive blood samples for pharmacokinetic analysis or three or more samples within one pharmacokinetic study period; 8. The volunteer is receiving or requires treatment that may affect the pharmacokinetic parameters of the study drug; 9. Occurrence of vomiting/diarrhea within 8 hours after administration of the study drug; 10. Positive urine test for narcotic substances and potent medicinal products; 11. Positive breath alcohol test; 12. Positive urine β-hCG test result in women; 13. Emergence of any other reason during study participation that, in the Investigator's judgment, precludes the subject's continued compliance with protocol requirements.

Locations (1)

Federal Budgetary Institution of Science "North-West Public Health Research Center"

Saint Petersburg, Russia

RECRUITING

Outcomes

Primary Outcomes

Pharmacokinetics - Cmax

Maximum plasma concentration (Cmax) of imidazolylethylamide of pentanedioic acid and N,N'-bis-\[2-(1,3-diazocyclopent-2,4-dien-4-yl)ethyl\] diamide of malonic acid. The same analytes would be used for other pharmacokinetic measures listed below.

Time frame: From 0 to 24 hours

Pharmacokinetics - tmax

Time to reach Cmax (tmax)

Time frame: From 0 to 24 hours

Pharmacokinetics - AUC0-t

Area under the plasma concentration-time curve from time 0 to t (AUC0-t)

Time frame: From 0 to 24 hours

Pharmacokinetics - AUC0-inf

Area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf)

Time frame: From 0 to 24 hours

Pharmacokinetics - AUCextr

Extrapolated AUC defined as (AUC0-inf - AUC0-t)/AUC0-inf

Time frame: From 0 to 24 hours

Pharmacokinetics - t1/2

Elimination half-life (t1/2)

Time frame: From 0 to 24 hours

Pharmacokinetics - kel

Elimination constant (kel)

Time frame: From 0 to 24 hours

Pharmacokinetics - number of terminal timepoints

Number of points in the terminal logarithmic phase used to estimate the terminal elimination rate constant

Time frame: From 0 to 24 hours

Secondary Outcomes

Adverse event type

Adverse events will be assessed by complaints, results of physical examination, results of heart rate and blood pressure assessment, results of respiratory rate assessment, body temperature, laboratory monitoring (clinical blood count, biochemical blood count, urinalysis), electrocardiography; adverse events will be classified in accordance to MedDRA.

Time frame: From Screening to Day 29 ± 1

Adverse event number

Number of adverse events registered during the study

Time frame: From Screening to Day 29 ± 1

Adverse event severety

Severity of adverse events registered during the study, assessed using the Common Terminology Criteria for Adverse Events (CTCAE)

Time frame: From Screening to Day 29 ± 1

Discontinuations due to adverse events related to the investigational product

Number of subjects who discontinued the study early due to adverse events (including serious adverse events) related to the investigational product

Time frame: From Screening to Day 29 ± 1

Safety and Tolerability: volunteer complaints

Description of any health-related complaints received from volunteer

Time frame: From Screening to Day 29 ± 1

Safety and Tolerability: physical examination results - cardiovascular system

An assessment of the condition of the cardiovascular system and associated symptoms on physical examination (normal condition or a description of abnormal conditions/cardiovascular symptoms, if any)